Medi-Cal Access Program

InspireSemi Provides Business Update

Retrieved on: 
星期五, 十一月 17, 2023
Thunderbird, Hilltop Holdings Inc., AI, Medi-Cal Access Program, HPC

VANCOUVER, British Columbia and AUSTIN, Texas, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Inspire Semiconductor Holdings Inc. (TSXV: INSP) (“InspireSemi” or the “Company”), a chip design company that provides revolutionary high-performance, energy-efficient accelerated computing solutions for HPC, AI, graph analytics, and other compute-intensive workloads, today provided a general business update.

Key Points: 
  • VANCOUVER, British Columbia and AUSTIN, Texas, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Inspire Semiconductor Holdings Inc. (TSXV: INSP) (“InspireSemi” or the “Company”), a chip design company that provides revolutionary high-performance, energy-efficient accelerated computing solutions for HPC, AI, graph analytics, and other compute-intensive workloads, today provided a general business update.
  • Added one customer under our Early Access Program (“EAP”), with two additional customers in the procurement stage (previously announced as commitments in the Company’s press release dated July 20, 2023)
    Delivered Thunderbird emulator board to a leading U.S. national laboratory
    Finalized design enhancements to our Thunderbird chip capabilities and completed a dry run tape out, with completion of final tape out dependent upon raising additional capital
    In addition to the non-brokered private placement previously announced in the Company’s press release dated October 31, 2023, the Company explains anticipated capital needs in the near and long-term

MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results

Retrieved on: 
星期四, 十一月 9, 2023
Biotechnology, Pharmaceutical, Health, Bone marrow, Annual general meeting, Charcot disease, European Medicines Agency, Maat, ICI, HSCT, Randomized controlled trial, CFO, ASH, Artificial intelligence, EMA, Patient, DSMB, PICASSO, Medi-Cal Access Program, Aryl hydrocarbon receptor, Hematopoietic stem cell transplantation, Immunotherapy, EUR, Therapy, Symantec Endpoint Protection, ORR, Cancer, Survival, MET, SITC, ARES, CGMP, Development, Society, Pharmaceutical industry, Vaccine, ALS

We are proud to achieve these milestones and we will continue to work on generating value for our shareholders,” stated Siân Crouzet, CFO of MaaT Pharma.

Key Points: 
  • We are proud to achieve these milestones and we will continue to work on generating value for our shareholders,” stated Siân Crouzet, CFO of MaaT Pharma.
  • MaaT Pharma reported revenues from its compassionate access program of EUR 0.4 million for the quarter ended September 30, 2023 comparable with the third quarter of 2022.
  • 2 The Company would like to correct a clerical error that was present in its Q2 results press release of July 27, 2023.
  • The EUR 0.9 million figure was the difference in revenue between H1 2023 and H1 2022 (EUR 1.4 million vs. EUR 0.5 million).

LeaseAccelerator Announces Enterprise Emissions Analysis and Reduction Software

Retrieved on: 
星期四, 十二月 14, 2023
CSRD, Intelligence, Medi-Cal Access Program, General ledger, ISSB, Software, ESG, Property management, Cryptocurrency, Lease

RESTON, Va., Dec. 14, 2023 /PRNewswire/ -- LeaseAccelerator, the leader in Enterprise Lease Lifecycle Management software, announced today the industry's first enterprise emissions analysis and reduction software for leases and assets, LeaseAccelerator Net Zero Asset Manager, along with an Early Access Program to help clients measure and reduce emissions in 2024.

Key Points: 
  • RESTON, Va., Dec. 14, 2023 /PRNewswire/ -- LeaseAccelerator, the leader in Enterprise Lease Lifecycle Management software, announced today the industry's first enterprise emissions analysis and reduction software for leases and assets, LeaseAccelerator Net Zero Asset Manager, along with an Early Access Program to help clients measure and reduce emissions in 2024.
  • Participants get early access to the software, preferential pricing, and a community committed to sharing feedback and best practices.
  • With LeaseAccelerator Net Zero Asset Manager , clients can:
    Collect, manage, and report on leased assets for emissions compliance and net-zero planning, leveraging usage data and emissions factors for real estate spaces and equipment.
  • "This gives controllers the same controls for emissions and lease accounting data in one asset-level subledger with one audit-trail and integrated business intelligence."

MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference

Retrieved on: 
星期四, 十一月 2, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, EAP, Survival, Policy, Medi-Cal Access Program, RCT, Society, ASH, Malignancy, Cancer, Patient, MET, DSMB, Pharmaceutical industry

In line with the conference embargo policy, MaaT Pharma will detail the presented results through a press release on Monday, December 11th, 2023.

Key Points: 
  • In line with the conference embargo policy, MaaT Pharma will detail the presented results through a press release on Monday, December 11th, 2023.
  • The Company will also host an investor webcast on Monday, December 18th, 2023, at 6:00pm CET (further details to follow).
  • MaaT013 is currently being evaluated in a pivotal Phase 3 trial (n=75) for corticosteroid- and ruxolitinib-refractory gastrointestinal aGvHD.
  • As of today, over 170 patients have been safely treated with MaaT013 in Europe in clinical trials and the EAP.

MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013

Retrieved on: 
星期四, 十月 26, 2023
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Steroid, Survival, Data analysis, Symantec Endpoint Protection, Graft-versus-host disease, Next, ARES, Medi-Cal Access Program, Access, Microbiota, ORR, Safety, Cancer, Patient, MET, Infection, DSMB, Pharmaceutical industry

Therefore, the DSMB concluded that the benefit/risk ratio with “high efficacy and low toxicity” was favorable in this patient population.

Key Points: 
  • Therefore, the DSMB concluded that the benefit/risk ratio with “high efficacy and low toxicity” was favorable in this patient population.
  • “We are delighted to report significant progress in the development of therapeutic solutions for patients battling severe acute GvHD.
  • Modulation of the microbiota is increasingly proving to be a breakthrough in the oncology field,” stated Hervé Affagard, CEO and co-founder of MaaT Pharma.
  • As per protocol, the DSMB met to review a specific safety and efficacy data analysis at Day 28, after inclusion of 30 patients.

Mayo Clinic to deploy and test Microsoft generative AI tools

Retrieved on: 
星期四, 九月 28, 2023
LLM, Mayo Clinic, Health, Microsoft Outlook, Synthetic media, Privacy, Microsoft, Organization, First officer (aviation), Patient, Microsoft Excel, Ethics, Mayo Clinic Center for Innovation, Medi-Cal Access Program, Safety, Nursing, Video game, Medical device

Mayo Clinic is testing the Microsoft 365 Copilot Early Access Program with hundreds of its clinical staff, doctors and healthcare workers.

Key Points: 
  • Mayo Clinic is testing the Microsoft 365 Copilot Early Access Program with hundreds of its clinical staff, doctors and healthcare workers.
  • Mayo Clinic is one of the first to start working with Copilot tools to enable staff experience across apps like Microsoft Outlook, Word, Excel and more.
  • "Privacy, ethics and safety are at the forefront of Mayo Clinic's work with generative AI and large language models," said Cris Ross, chief information officer at Mayo Clinic.
  • By using generative AI and LLMs, Mayo Clinic will be able to offer its teams new timesaving tools to help them succeed.

First Customers Receive World's Most Powerful Edge AI Solutions from Axelera AI

Retrieved on: 
星期二, 九月 12, 2023
Software, Hardware, Start-Up, Artificial Intelligence, Data Management, Professional Services, Technology, Other Technology, Cloud, PCI Express, Multimedia, Access, Medi-Cal Access Program, Metis, Medical device, AI

Axelera AI , provider of world’s most powerful and advanced solutions for AI at the Edge, today announced the first shipment of its Metis™ AI Platform to its Early Access Program customers.

Key Points: 
  • Axelera AI , provider of world’s most powerful and advanced solutions for AI at the Edge, today announced the first shipment of its Metis™ AI Platform to its Early Access Program customers.
  • To learn more about Axelera AI at the AI Hardware & Edge AI Summit, click here .
  • The Metis AI Platform offers practical Edge AI inference solutions, catering to companies developing next-generation computer vision applications.
  • At the AI Hardware & Edge AI Summit 2023 in Santa Clara, taking place from September 12-14, Axelera AI will be presenting on how to successfully bridge the Cloud-Edge AI Gap.

iManage Launches iManage Insight+, a Cloud-Native Knowledge Curation and Search Solution

Retrieved on: 
星期二, 八月 22, 2023
Knowledge, Metadata, WBD, Synthetic media, Lawyer, Rapid application development, Organization, Development Management Institute, Medi-Cal Access Program, Artifact, PII, IManager, Risk management, Cloud

CHICAGO and LONDON, Aug. 22, 2023 (GLOBE NEWSWIRE) -- iManage , the company dedicated to Making Knowledge WorkTM, today announced the launch of iManage Insight+, a knowledge search and management solution, built natively in the iManage Cloud platform.

Key Points: 
  • CHICAGO and LONDON, Aug. 22, 2023 (GLOBE NEWSWIRE) -- iManage , the company dedicated to Making Knowledge WorkTM, today announced the launch of iManage Insight+, a knowledge search and management solution, built natively in the iManage Cloud platform.
  • “Insight+ is an important enhancement to the value delivered by the iManage platform,” said Neil Araujo, CEO of iManage.
  • The initial release of Insight+ includes two distinct search experiences, or Locators: Search & Find, and Knowledge Locator.
  • Knowledge Locator narrows a search to specific assets curated by knowledge administrators, including the best practices content, artifacts, and templates that constitute a firm’s institutional knowledge.

InspireSemi Provides Business Update Including Early Access Program Customer Commitments and Performance Benchmarks

Retrieved on: 
星期四, 七月 20, 2023
Cartoon Network, LP v. CSC Holdings, Inc., Government, CPU, HPC, Architecture, Medi-Cal Access Program, GPU, High-performance computing, Cryptocurrency, Pharmaceutical industry, Video game, Thunderbird

VANCOUVER, British Columbia and AUSTIN, Texas, July 20, 2023 (GLOBE NEWSWIRE) -- Inspire Semiconductor Holdings Inc. (TSXV: INSP) (“InspireSemi” or the “Company”), a chip design company that has built a technology foundation to deliver best-in-class accelerated computing performance, today provided a business update, including customer commitments derived from the Company’s Early Access Program and key High Performance Computing (HPC) application benchmarks.

Key Points: 
  • VANCOUVER, British Columbia and AUSTIN, Texas, July 20, 2023 (GLOBE NEWSWIRE) -- Inspire Semiconductor Holdings Inc. (TSXV: INSP) (“InspireSemi” or the “Company”), a chip design company that has built a technology foundation to deliver best-in-class accelerated computing performance, today provided a business update, including customer commitments derived from the Company’s Early Access Program and key High Performance Computing (HPC) application benchmarks.
  • A recording of the business update will be made available in the Investors Relations section of the Company’s website at https://inspiresemi.com/investors/ .
  • “We are excited to provide this business update as we prepare to bring to market a disruptive, next generation hardware compute accelerator that can address the ever growing needs of HPC users,” said Ron Van Dell, CEO of InspireSemi.
  • Our solution represents an industry solution that offers best-in-class return on investment for performance, energy efficiency, versatility, and affordability.”
    Early Access Program and Commitments:
    Recently, InspireSemi introduced its Early Access Program for select customers interested in obtaining early access to InspireSemi’s new Thunderbird accelerator chip.

Impact Observatory Launches IO Monitor to Understand Climate, Financial, and Environmental Risk in Near Real-Time

Retrieved on: 
星期一, 五月 22, 2023
Water pollution, IO, Deforestation, Forest, Natural Resources, Drought, Biodiversity, Flood, Climate change, Soil, Water supply, Map, Climate, City, Sole Food Street Farms, Sustainable sourcing, Medi-Cal Access Program, AWS, Food, Video game, Satellite navigation device, Agriculture, Risk management

IO Monitor enables global decision makers to better understand financial, climate, and environmental risk in near real-time at previously unobtainable speed and scale.

Key Points: 
  • IO Monitor enables global decision makers to better understand financial, climate, and environmental risk in near real-time at previously unobtainable speed and scale.
  • What makes IO Monitor unique is Impact Observatory’s deep learning approach, which automates and accelerates space-based mapping and monitoring to classify Land Use Land Cover (LULC) categories globally.
  • With IO Monitor, customers get on-demand access to the most up-to-date global land cover maps based on the most recent satellite imagery available.
  • Impact Observatory enables government leaders to monitor the entire world in near real-time without over tasking national assets.